Clinical Cancer Research Landon Prizes for Basic and Translational Cancer Research Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shibata, H.
Right arrow Articles by Matsumoto, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shibata, H.
Right arrow Articles by Matsumoto, T.
Clinical Cancer Research Vol. 11, 6109-6115, September 1, 2005
© 2005 American Association for Cancer Research

Human Cancer Biology

Malignant B-Lymphoid Cells with Bone Lesions Express Receptor Activator of Nuclear Factor-{kappa}B Ligand and Vascular Endothelial Growth Factor to Enhance Osteoclastogenesis

Hironobu Shibata1, Masahiro Abe1, Kenji Hiura2, Javier Wilde2, Keiji Moriyama2, Toshiaki Sano3, Ken-ichi Kitazoe1, Toshihiro Hashimoto1, Shuji Ozaki4, Shingo Wakatsuki5, Shinsuke Kido1, Daisuke Inoue1 and Toshio Matsumoto1

Authors' Affiliations: Departments of 1 Medicine and Bioregulatory Sciences, 2 Orthodontics, and 3 Human Pathology, University of Tokushima Graduate School of Health Biosciences; 4 Division of Transfusion Medicine, Tokushima University Hospital, Tokushima, Japan; and 5 Division of Pathology, Hyogo Prefectural Awaji Hospital, Hyogo, Japan

Requests for reprints: Masahiro Abe, Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan. Phone: 81-88-633-7120; Fax: 81-88-633-7121; E-mail: masabe{at}clin.med.tokushima-u.ac.jp.


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
Purpose: Receptor activator of nuclear factor-{kappa}B ligand (RANKL) is a key mediator of osteoclastogenesis. Because certain types of tumor cells aberrantly express RANKL, and because bone destruction also develops in B-cell lymphomas of bone origin, we investigated RANKL expression and the mechanisms of osteoclastogenesis in B-lymphoid neoplasms.

Experimental Design and Results: Immunohistochemistry of bone specimens resected from patients with primary B-cell lymphoma of bone with bone destruction revealed that lymphoma cells express RANKL as well as vascular endothelial cell growth factor (VEGF). The tumor cells isolated from the bone specimens enhanced osteoclastogenesis in vitro. In contrast, B-cell lymphoma infiltrating to the bone marrow without bone destruction did not express RANKL. Both RANKL and VEGF were expressed by a portion of B-lymphoid cell lines, including Daudi and IM-9. These RANKL-expressing tumor cells enhanced osteoclastogenesis from RAW264.7 cells and human monocyte-derived preosteoclasts in the absence of stromal cells/osteoblasts in a RANKL-dependent manner. Furthermore, conditioned media from Daudi cells enhanced transmigration of preosteoclasts that was inhibited by anti-VEGF antibody, suggesting that tumor cell–derived VEGF mediates recruitment of osteoclast precursors. Moreover, cocultures of B-lymphoid cell lines with osteoclasts enhanced the growth of B-lymphoid cells.

Conclusions: Some malignant B cells aberrantly express functional RANKL as well as VEGF to enhance osteoclastogenesis. The coexpression of RANKL and VEGF may also contribute to the close cellular interactions with osteoclastic cells, thereby forming a vicious cycle between osteoclastic bone destruction and tumor expansion in bone.

Certain types of B-lymphoid neoplasms, such as lymphoma of bone origin and multiple myeloma, exclusively develop and expand in the skeleton. These tumors cause lytic bone lesions, which lead to the debilitating clinical symptoms including intractable bone pain and disabling fractures. In those destructive bone lesions, osteoclasts seem to surround tumor cells and actively resorb bone. Several bone-resorbing factors, including parathyroid hormone–related protein (1), interleukin (IL)-1ß (2–4), and IL-6 (3–5), have been implicated as causative factors for bone destruction in multiple myeloma, and recent reports including those from ourselves indicate that a C-C chemokine, macrophage inflammatory protein-1{alpha} and macrophage inflammatory protein-1ß, plays an important role in the development of lytic bone lesions by multiple myeloma (6–10). However, the pathogenesis as well as the mechanism of bone destruction by B-cell lymphoma of bone origin is largely unknown.

Binding of receptor activator of nuclear factor-{kappa}B ligand (RANKL; refs. 11–13) to its receptor (RANK; ref. 14) is essential for the enhancement of osteoclast differentiation, activation, and survival, whereas its decoy receptor, osteoprotegerin (15), inhibits RANKL-RANK signaling. Along with RANKL, macrophage colony-stimulating factor (M-CSF) is required to enhance osteoclastogenesis (16). Recent reports showed that vascular endothelial cell growth factor (VEGF) can substitute for M-CSF and that VEGF and RANKL in combination potently stimulate osteoclastogenesis (17). Growing evidence indicates that tumor cells stimulate osteoclastogenesis by enhancing RANKL expression and suppressing osteoprotegerin in the surrounding cells or by themselves to form destructive bone lesions in multiple myeloma and metastatic bone diseases (18–23). Expression of RANKL by tumor cells has been reported in adult T-cell leukemia (24), pre–B-cell leukemia (25), multiple myeloma (26–28), and prostate cancer (29, 30). Furthermore, the expression levels of RANKL on tumor cells have been found to correlate with the severity of lytic bone lesions in multiple myeloma (27, 28) and hypercalcemia in adult T-cell leukemia (24), suggesting a causative role for RANKL on tumor cells in the development of lytic bone lesions. Although RANKL is shown to be expressed on CD20-positive B cells in the bone marrow (31) and induced by activated B cells (32), RANKL expression on B-lymphoid neoplasms other than pre–B-cell leukemia and multiple myeloma has been poorly examined. Here, we show that a portion of B-lymphoid tumor cell lines as well as primary B-lymphoid tumor cells of bone origin aberrantly express RANKL and VEGF, and directly induce osteoclastogenesis from osteoclast progenitors via cell-to-cell contact. The present results also show that a close interaction between B-lymphoid tumor cells and osteoclasts augments mutual growth and activity.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Reagents. The following reagents were purchased from the indicated manufacturers: recombinant human (rh) soluble RANKL (sRANKL) from Pepro Tech (London, United Kingdom); rhM-CSF, rhVEGF, mouse monoclonal antibodies against human RANKL (TRANCE), IL-1ß, IL-6, and CD68 from R&D Systems (Minneapolis, MN); anti-human RANKL, RANK, osteoprotegerin, VEGF, parathyroid hormone–related protein monoclonal antibody from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA); antihuman CD20 monoclonal antibody from Becton Dickinson (Mountain View, CA); antitartrate-resistant acid phosphatase (TRAP) antibody from Novocastra (Newcastle-upon-tyne, United Kingdom); antihuman macrophage inflammatory protein-1{alpha} monoclonal antibody from Chemicon International, Inc. (Temecula, CA). Recombinant human osteoprotegerin was a kind gift from Dr Tadaaki Higashio (Saitama Medical University, Saitama, Japan).

Primary lymphoma samples from patients. Lymphoma samples in bone were obtained from two patients with primary bone lymphoma manifesting bone destruction (cases 1 and 2) and from eight patients with B-cell lymphoma (four follicular lymphoma, two splenic marginal zone lymphoma, and two mantle cell lymphoma) secondarily infiltrating to the bone marrow without apparent bone destruction. Lymph node tissues were also obtained from 19 patients with nodal lymphoma without bone involvement (10 diffuse large, 5 follicular, and 4 marginal cell lymphoma), and skin specimens from two patients with diffuse large lymphoma. Case 1 showed intraspinal mass in the 11th thoracic vertebra (T11) and T12 with a compression fracture of T11. The spinal lesions were resected because of a rapid progression of spinal cord compression. Pathologic studies on the resected specimen revealed diffuse infiltration of large B-lymphoid cells. A diagnosis of diffuse large B-cell lymphoma was made. Case 2 showed lytic bone lesions at multiple sites in the limbs and the right clavicle. Open biopsy of the osteolytic lesion of the left radius yielded the histologic diagnosis of diffuse large B-cell lymphoma.

Informed consent was obtained from all the patients, and all procedures involving human specimens were done according to the protocol approved by the Institutional Review Board for human protection.

Cells and cultures. Human B-lymphoid cell lines, ARH77, IM-9, Raji, Daudi and Ramos, human myeloma cell lines, U266 and RPMI8226, a human osteoblast-like cell line, MG-63, and a murine preosteoclastic cell line, RAW264.7 were obtained from the American Type Culture Collection (Rockville, MD). Human myeloma cell lines TSPC-1 and OPC were established in our laboratory as previously described (6). Mononuclear cells were isolated by Ficoll-Hypaque density gradient centrifugation from heparinized blood drawn from healthy volunteers and resected tumors in the bone and lymph nodes. Primary B-lymphoid tumor cells were further purified by immunomagnetic cell sorting using an antihuman CD19 antibody conjugated to magnetic beads (MACS system, Miltenyi Biotec, Bergisch, Gladbach, Germany).

Immunohistochemistry. Tissue sections were prepared from 10% formalin-fixed, paraffin-embedded resected tumors and bone marrow aspirates. They were stained with H&E (Sigma, St. Louis, MO). The tissue sections were deparaffinized, rehydrated, and treated with 3% H2O2 for 30 minutes to inactivate endogenous peroxidase activity. After blocking with DAKO protein block (DAKO, Carpinteria, CA), sections were incubated with anti-CD20, IL-1ß, IL-6, CD68, RANKL, VEGF, parathyroid hormone–related protein and TRAP antibodies, followed by the detection with the standard detection system (LSAB kit; DAKO) containing peroxidase-conjugated secondary antibodies and diaminobenzidine as a chromogen. The cells were visualized with a microscope (BX50; Olympus, Tokyo, Japan) using UPlanFl x40 objective lens. Images were recorded with a Olympus CCD camera (SC35, Olympus) and Viewfinder Light software (Pixera Corporation, Los Gatos, CA), and digitally processed using Photoshop software (Adobe, San Jose, CA).

Flow cytometry. Cells were incubated with saturating concentrations of FITC-conjugated antibodies on ice for 1 hour. For indirect fluorescence staining, cells were incubated first with primary antibodies on ice for 1 hour, washed, and then incubated with FITC-conjugated secondary antibodies on ice for 30 minutes. Samples were analyzed by flow cytometry using EPICS-Profile (Coulter Electronics, Hialeah, FL).

Cocultures of primary bone lymphoma cells with rabbit bone cells. Rabbit bone marrow cells were prepared from unfractionated bone cells according to previously described procedures with slight modification (33). In brief, minced long bones of 5-day-old male white rabbits were agitated by vortexing and bone particles were removed by sedimentation for 30 seconds in Eagle's {alpha}-MEM modification (Invitrogen, Carlsbad, CA). After centrifugation at 300 x g for 3 minutes, two thirds of the supernatant from the top were removed to enrich osteoclast precursors. Thus, obtained fractions of rabbit bone cells were seeded in 96-well plates containing a bovine dentine at 5 x 103 cells/well in {alpha}-MEM containing 10% fetal bovine serum (Whittaker Bioproducts, Inc., Walkersville, MA). Isolated lymphoma cells at 2 x 103 cells/well were cocultured. At day 4, the number of TRAP-positive multinucleated cells was counted. Subsequently, cells were blushed off and bone slices were stained with hematoxylin for 5 minutes to visualize resorption pits. For quantification, the number of mesh squares covering the pits was counted using a microscope with a mesh glass installed in the ocular lens.

In vitro osteoclastogenesis. RAW264.7 cells were seeded in 96-well plates at 5 x 104 cells/well and cultured for 96 hours in {alpha}-MEM containing 10% fetal bovine serum in the absence or presence of 50 ng/mL sRANKL. For coculture experiments, B-lymphoid cells (2 x 103 cells) were added to the wells precultured with RAW264.7 cells. After 4 days, the cultured cells were stained for TRAP using Leukocyte Acid Phosphatase kit (Sigma) and the number of TRAP-positive multinucleated cells was counted.

In vitro osteoclast generation from peripheral blood mononuclear cell (PBMC) was done as previously described (34). Briefly, an adherent cell population was collected and cultured at 1 x 105 cells/mL in {alpha}-MEM containing 10% fetal bovine serum supplemented with 50 ng/mL sRANKL and 500 units/mL M-CSF. Media were replenished twice a week. After 2 weeks, most of adherent cells were still mononuclear and became TRAP positive, and the adherent cells were harvested using 0.05% trypsin/0.53 mmol/L EDTA (Invitrogen). The cells were replated onto 24-well plates at 5 x 104 cells/well, and cocultured with Daudi cells (1 x 104 cells/well). A membrane filter (Intercell TP, Kurabo, Osaka, Japan) was used to prevent cell-to-cell contact. After 5 days, the number of TRAP-positive multinucleated cells was counted.

Collection of conditioned media and cytokine measurement. The B-lymphoid cell lines were cultured in {alpha}-MEM with 1% fetal bovine serum at 1 x 106 cells/mL. Conditioned media were harvested at day 2. Human sRANKL and osteoprotegerin were measured by sRANKL and osteoprotegerin kit (Biomedica GmbH, Wien, Austria), respectively; VEGF and M-CSF levels were determined by hVEGF and hM-CSF kit (Quantikine, R&D), respectively.

Migration assays. Cell migration assays were done using membrane filters with 8 µm pore–sized transmigration chambers (Chemotaxicell, Kurabo, Japan). Peripheral blood–derived TRAP-positive mononuclear cells were placed on upper chambers in 400 µL of {alpha}-MEM containing 1% fetal bovine serum. Lower chambers were filled with 800 µL of the same medium. Conditioned media from Daudi was added at 10% to either upper or lower chambers or both. Anti-VEGF antibody was added at 20 µg/mL. As a positive control, recombinant VEGF was added to lower chambers at 10 ng/mL. The plates were incubated at 37°C for 4 hours in a 5% CO2 incubator. After 4-hour incubation, nonmigrated cells on the upper side on membrane filters were removed with a cotton swab and the cells migrated to the bottom of filters were fixed with formalin and stained with Giemsa solution (Merck, Tokyo, Japan). The filters were dried, cut out, and mounted with permount solution (Thomas Scientific, Swedesboro, NJ) on a glass slide. Cells were viewed under a microscope and cell numbers were counted.

Analyses of messenger RNA expression. Total RNA was extracted from cells using TRIzol reagent (Invitrogen). For reverse transcription-PCR, 2 µg total RNA were reverse-transcribed with Superscript II (Invitrogen) in a 20 µL reaction solution. Two microliters of the 20 µL reaction solution were used for the subsequent PCR analyses with cycles of 95°C for 30 seconds, 56°C for 30 seconds, and 72°C for 30 seconds. Primers used are as follows: 5'-GGATCACAGCACATCAGAGCAGAG-3' (nucleotides 590-613) and 5'-GTAAGGAGGGGTTGGAGACCTCG-3' (nucleotides 1,079-1,057) for human RANKL and 5'-TGTCTTCACCACCATGGAGAAGG-3' (nucleotides 340-362) and 5'-GTGGATGCAGGGATGATGTTCTG-3' (nucleotides 762-750) for human glyceraldehyde-3-phosphate dehydrogenase. Amplified products were dissolved in a 2% agarose gel and visualized with ethidium bromide staining.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
Receptor activator of nuclear factor-{kappa}B ligand expression and osteoclastogenesis by primary bone B-cell lymphoma cells. To clarify whether lymphoma cells aberrantly express RANKL to cause bone destruction, we first immunohistochemically examined RANKL expression in bone tissue samples obtained from patients with primary bone lymphoma and nodal lymphoma infiltrating to the bone marrow without bone destruction. RANKL was found to be expressed by B-lymphoid tumor cells only from patients with primary bone lymphoma (Fig. 1A). We further investigated RANKL expression by lymphoma cells in B-cell non–Hodgkin's lymphoma without bone destruction. We found RANKL expression by lymphoma cells in only 2 of 19 lymph node samples from patients with systemic nodal lymphoma. We also examined eight bone marrow specimens secondarily infiltrated by lymphoma cells, but there was no detectable RANKL expression by lymphoma cells (data not shown). No RANKL expression was detectable in two cutaneous lymphoma specimens (data not shown). We also did immunohistochemical staining of RANK and osteoprotegerin in the same B-cell lymphoma sections in addition to RANKL. However, we were able to detect neither RANK nor osteoprotegerin immunoreactivity in lymphoma cells in any sections studied (data not shown), suggesting very little or no expression of RANK and osteoprotegerin at protein levels in B-cell non–Hodgkin's lymphoma. In primary bone lymphoma, tumor cells showed positive staining for VEGF along with RANKL (Fig. 1A). No immunoreactivity was detected for other known osteoclastogenic factors, including IL-1ß, IL-6, and parathyroid hormone–related protein (data not shown). TRAP- and CD68-positive osteoclasts were observed adjacent to eroded bone surfaces, indicating active bone resorption in these sites (Fig. 1B). Interestingly, lymphoma cells were surrounded by a number of TRAP- and CD68-positive mononuclear cells, namely preosteoclasts or immature cells of osteoclastic lineage (Fig. 1B). These observations suggest a close cell-to-cell interaction between lymphoma cells and such cells of osteoclastic lineage. In flow cytometric analyses, RANKL was expressed on the surface of lymphoma cells from a patient with primary bone lymphoma, whereas tumor cells from a patient with nodal B-cell lymphoma did not express RANKL on their surface (Fig. 1C). Functional activity of RANKL expressed on the tumor cells was corroborated by coculturing the osseous lymphoma cells with an osteoclast-enriched fraction of rabbit bone cells on dentine slices. The RANKL-expressing tumor cells potently enhanced TRAP-positive multinucleated cell and pit formation, which were almost totally abrogated by addition of excess osteoprotegerin (Fig. 1D).



View larger version (50K):
[in this window]
[in a new window]
  		Fig. 1. A, immunoreactivity of RANKL and VEGF in primary bone lymphoma. Tumor cells in the bone specimens resected from case 1 (left) and case 2 (right) showed immunoreactivity for RANKL and VEGF (x400). B, immunoreactivity of CD68 and TRAP in the bone specimen (case 1). CD68- and TRAP-positive osteoclasts surrounded the tumor and adjacent bone surfaces were eroded. A number of CD68- and TRAP-positive mononuclear cells, namely immature osteoclastic lineage cells or preosteoclasts, diffusely appeared and intermingled with the tumor cells (x400). C, RANKL expression by primary lymphoma cells isolated from the bone specimen from case 1 (left) and from lymph node from a patient with nodal non–Hodgkin's lymphoma (right) by flow cytometry. D, osteoclast formation and function by primary bone lymphoma cells. Primary lymphoma cells isolated from case 1 were cocultured with rabbit bone cells on dentine slices, and TRAP-positive multinucleated cell and pit number was counted at day 4 as described in Materials and Methods. Columns, means; bars, SD. *Significantly different by one-way ANOVA with Scheffe post hoc tests, P < 0.05.

 
Expression of receptor activator of nuclear factor-{kappa}B ligand by B-lymphoid cell lines. To further clarify whether B-lymphoid tumor cells aberrantly express RANKL, we next examined RANKL expression in B-lymphoid tumor cell lines exhibiting mature B-cell or plasma cell phenotypes. Among the cell lines tested, we found constitutive expression of RANKL mRNA in ARH77, IM-9, and Daudi B-cell lines and faintly in TSPC-1 myeloma cell line (Fig. 2A). Cell surface expression of RANKL protein was further confirmed by flow cytometry. RANKL protein was strongly expressed on IM-9 and Daudi cells, which paralleled with the mRNA levels (Fig. 2B). We did not detect sRANKL immunoreactivity in culture supernatants of these cell lines, suggesting that cell-to-cell contact is required for RANKL binding to its receptor, RANK. Although osteoprotegerin, a soluble inhibitor of RANKL, is also known to be produced by various types of tumor cells (35, 36), none of the B-lymphoid cell lines secreted detectable levels of osteoprotegerin in culture supernatants. Thus, RANKL expressed on the surface of the tumor cells acts via cell-to-cell contact without inhibition by osteoprotegerin.



View larger version (27K):
[in this window]
[in a new window]
  		Fig. 2. A, expression of RANKL mRNA in zB-lymphoid tumor cell lines. Cell lines used were U266 (lane 1), RPMI8226 (lane 2), ARH-77 (lane 3), IM-9 (lane 4), TSPC-1 (lane 5), OPC (lane 6), Raji (lane 7), Daudi (lane 8), and Ramos (lane 9). B, surface expression of RANKL on IM-9 and Daudi cells was analyzed by flow cytometry. Solid and dotted lines denote levels of RANKL expression and the background, respectively.

 
Osteoclastic differentiation from RAW264.7 cells in the presence of receptor activator of nuclear factor-{kappa}B ligand–expressing B-lymphoid cell lines. To clarify whether RANKL aberrantly expressed on B-lymphoid tumor cells plays any functional role, we cocultured RAW264.7 preosteoclastic cells with IM-9 and Daudi cells. As shown in Fig. 3A, RAW264.7 cells differentiated into TRAP-positive multinucleated cells upon RANKL stimulation alone even in the absence of stromal cells/osteoblasts. The cocultures with IM-9 or Daudi cells potently enhanced TRAP-positive multinucleated cell formation from RAW264.7 cells. The enhancement of osteoclastogenesis by IM-9 and Daudi cells was mostly abrogated by addition of osteoprotegerin, indicating a critical role for RANKL expressed on these cells in the enhancement of osteoclastogenesis.



View larger version (15K):
[in this window]
[in a new window]
  		Fig. 3. A, osteoclastogenesis from RAW264.7 cells in the presence of IM-9 and Daudi cells. RAW264.7 cells (5 x 104 cells/well) were cultured with rh sRANKL at 100 ng/mL, or cocultured with 2 x 103 cells/well of IM-9 or Daudi cells in quadruplicate in 24-well culture plates in the presence (open columns) or absence (filled columns) of osteoprotegerin at 1 µg/mL. TRAP-positive multinucleated cells were counted at day 4. B, osteoclastogenesis from PBMC-derived TRAP-positive mononuclear cells by Daudi cells. TRAP-positive mononuclear cells derived from PBMC were cultured with rh sRANKL at 100 ng/mL, or cocultured with Daudi cells in quadruplicate in the presence (open columns) or absence (filled columns) of osteoprotegerin at 1 µg/mL. Membrane filters were used to prevent cell-to-cell contact between Daudi cells and TRAP-positive mononuclear cells. Columns, means of TRAP-positive multinucleated cell number; bars, SD. *Significantly different by one-way ANOVA with Scheffe post hoc tests, P < 0.05.

 
Osteoclast formation from human peripheral blood mononuclear cell–derived preosteoclasts through cell-to-cell contact with Daudi cells. The osteoclastogenic activity of RANKL expressed on B-lymphoid tumor cells was further confirmed by coculturing with human preosteoclasts derived from PBMC. Addition of sRANKL alone substantially enhanced formation of multinucleated cells from PBMC-derived preosteoclasts (Fig. 3B). These multinucleated cells possessed the hallmark of osteoclasts, including expression of calcitonin receptors and ability to form pits on dentine slices as well as positive staining for TRAP (data not shown). Similarly, when Daudi cells were cocultured with PBMC-derived preosteoclasts, osteoclast formation was even more enhanced (Fig. 3B). Again, exogenous osteoprotegerin mostly abrogated the osteoclast formation enhanced by Daudi cells as well as sRANKL. Furthermore, inhibition of cellular contact by membrane filters strongly suppressed the osteoclast formation. These observations show that cell-to-cell contact is required for the osteoprotegerin-inhibitable enhancement of osteoclast formation by Daudi cells.

Vascular endothelial growth factor secretion by B-lymphoid cell lines. Although the presence of both RANKL and M-CSF is required for osteoclastogenesis, B-lymphoid tumor cells do not costitutively produce M-CSF. Because VEGF can substitute for M-CSF in osteoclastogenesis (17), we examined the secretion of VEGF by B-lymphoid tumor cells. As shown in Table 1, all B-lymphoid cell lines, including IM-9 and Daudi, constitutively secreted VEGF into culture supernatants. Thus, by expressing both RANKL and VEGF, B-lymphoid tumor cells can enhance osteoclastogenesis by themselves even in the absence of stromal cells/osteoblasts.


View this table:
[in this window]
[in a new window]
  		Table 1. VEGF production by human B-lymphoid cell lines

 
Transmigration of peripheral blood mononuclear cell–derived preosteoclasts by Daudi cells. We next examined how RANKL-expressing tumor cells can effectively interact with osteoclast precursors. For this purpose, we conducted transmigration assays to clarify whether tumor cells can attract preosteoclasts toward tumor cells. When Daudi cell–conditioned media was added to chambers beneath transmigration pore membranes, a substantial number of PBMC-derived preosteoclasts migrated to the lower side of the membranes (Fig. 4). When Daudi cell–conditioned media was added to both upper and lower chambers or to only upper chambers, downward transmigration was not enhanced. These results are consistent with the assumption that Daudi cell–derived soluble factors induce chemotaxis of preosteoclasts toward Daudi cells. VEGF is known to exert chemotactic effects on various types of cells, including cells of osteoclastic lineage (37, 38). Because VEGF is secreted by B-lymphoid tumor cells (Table 1), we next examined chemotactic effects of tumor-derived VEGF on preosteoclasts. As shown in Fig. 4, rhVEGF potently enhanced transmigration of preosteoclasts, and a neutralizing antibody against VEGF significantly suppressed transmigration induced by Daudi cell–conditioned media. These results show that tumor cell–derived VEGF, at least in part, contributes to chemoattraction of osteoclast precursor cells.



View larger version (14K):
[in this window]
[in a new window]
  		Fig. 4. Migration of PBMC-derived TRAP-positive mononuclear cells by conditioned media from Daudi cells. Conditioned media from Daudi cells were added to upper or lower chambers at 10% as indicated, and rhVEGF was to lower chambers at 10 ng/mL. Anti-VEGF neutralizing antibody or control IgG was added at 20 µg/mL to the indicated chambers. PBMC-derived TRAP-positive mononuclear cells (1 x 105/mL) were placed onto the upper chambers in quadruplicate and allowed to migrate for 4 hours. The numbers of the migrated cells to the bottom of pore filters was counted. Columns, means of migrated cell numbers; bars, SD. *, Significantly different by one-way ANOVA with Scheffe post hoc tests, P < 0.05.

 
Growth enhancement of B-lymphoid cell lines by osteoclasts. In addition to osteoclastogenesis induced by a close interaction between B-lymphoid tumor cells and cells of osteoclastic lineage, we asked whether such a cellular interplay also enhances tumor growth and survival. To answer this question, we cocultured Daudi cells with PBMC-derived osteoclasts. Proliferation of Daudi cells was found to be enhanced in the presence of osteoclasts (Fig. 5). The growth-promoting effect of osteoclasts was also observed in other B-lymphoid tumor cells, including Ramos, OPC, TSPC-1, U266, and RPMI8226 (data not shown), suggesting that osteoclasts have growth-promoting effects on a majority of B-lymphoid tumor cells.



View larger version (9K):
[in this window]
[in a new window]
  		Fig. 5. Growth enhancement of Daudi cells in the presence of PBMC-derived osteoclasts. Daudi cells (1 x 105/mL) were cultured in quadruplicate in the presence or absence of PBMC-derived osteoclasts. Daudi cell number was counted at the indicated time points. Columns, means; bars, SD.

 

   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
The present study shows that RANKL is expressed in some B-lymphoid cell lines as well as in B-lymphoid tumor cells from patients with bone destructive lesions, but not in those with bone marrow infiltration without destructive bone lesions. Such RANKL-expressing B-lymphoid tumor cells also produced VEGF, a substitute for M-CSF, thereby efficaciously inducing osteoclastogenesis even in the absence of stromal cells. For the development of bone lesions by prostate cancer (29) and humoral hypercalcemia by squamous cell carcinoma (39), secretion of soluble form of RANKL has been reported. However, immunoreactivity for RANKL was not detected in conditioned media of any of B-lymphoid cell lines. In addition, the enhancement of osteoclastogenesis by these tumor cells was abrogated by an addition of osteoprotegerin or an inhibition of cell-to-cell contact by membrane filters. These results support the notion that RANKL expressed on the surface of B-lymphoid tumor cells enhances osteoclastogenesis upon its cell-to-cell contact-mediated binding to RANK on preosteoclastic cells.

Although tumor cells express RANKL on their surface, osteoclast formation may not be enhanced unless enough number of osteoclast precursors get close contact with tumor cells. The present results show that conditioned media of B-lymphoid tumor cell cultures enhanced chemoattraction of preosteoclasts and that an anti-VEGF antibody mostly abrogated the enhancement. Furthermore, immunohistochemical examination of bone specimens from patients with primary bone lymphoma with bone destructive lesions revealed that RANKL- and VEGF-positive tumor cells were surrounded by CD68- and TRAP-positive cells of osteoclastic lineage. Thus, it is suggested that B-lymphoid tumor cells secrete VEGF to enhance osteoclastic bone resorption by not only enhancing osteoclastogenesis in cooperation with RANKL but also recruiting osteoclast precursors via its chemoattractant activity.

We observed RANKL expression in two lymph node samples of 19 patients with non–Hodgkin's lymphoma without bone involvement, suggesting that B-cell lymphoma cells rarely express RANKL when it develops in lymph nodes. We did not detect RANKL immunoreactivity in lymphoma cells infiltrating to the bone marrow in eight patients with systemic nodal lymphoma showing no apparent bone lesions. Interestingly, however, a case with follicular lymphoma infiltrating to the bone marrow was reported to show RANKL expression by lymphoma cells and enhancement of osteoclastic bone destruction (40). Therefore, RANKL is aberrantly expressed only in a limited number of B-cell non–Hodgkin's lymphoma clones, but once expressed it may promote osteoclastic bone destruction particularly when such lymphoma cells arise in or infiltrate to the bone marrow. However, the number of the analyzed specimens is small and more extensive study is required to establish clinical relevance of RANKL expression to bone destructive lesions in B-cell non–Hodgkin's lymphoma.

The present study also showed that cell-to-cell contact between B-lymphoid tumor cells and cells of osteoclastic lineage enhances not only osteoclastogenesis but also the growth of lymphoma cells. Thus, whereas B-lymphoid tumor cells stimulate bone destruction by enhancing osteoclastogenesis, the growth of B-lymphoid tumor cells harboring in bone is enhanced by cell-to-cell interaction with osteoclasts. Taken together, the present observations suggest that B-lymphoid tumors of bone origin expand by a cellular interplay between lymphoma cells and cells of osteoclastic lineage and that there is a vicious cycle between bone destruction and tumor expansion in bone.


   Acknowledgments
 
We thank Momoko Nitta, Hiroe Amou, and Asuka Oda for their expert technical assistance.


   Footnotes
 
Grant support: Scientific Research on Priority Areas B (T. Matsumoto) Grants-in-Aid for Scientific Research B and C (T. Matsumoto and M. Abe, respectively), and a grant for 21st century Center of Excellence Program from the Ministry of Education, Culture, Science and Sports of Japan.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

Received 1/31/05; revised 6/ 3/05; accepted 6/21/05.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Suzuki A, Takahashi T, Okuno Y, et al. Production of parathyroid hormone-related protein by cultured human myeloma cells. Am J Hematol 1994;45:88–90.[Medline]
  2. Yamamoto I, Kawano M, Sone T, et al. Production of interleukin 1ß, a potent bone resorbing cytokine, by cultured human myeloma cells. Cancer Res 1989;49:4242–6.[Abstract/Free Full Text]
  3. Bataille R, Chappard D, Klein B. The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma. Int J Clin Lab Res 1992;21:283–7.[Medline]
  4. Abildgaard N, Glerup H, Rungby J, et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 2000;64:121–9.[CrossRef][Medline]
  5. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993;82:3712–20.[Abstract/Free Full Text]
  6. Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)-1{alpha} and MIP-1ß in the development of osteolytic lesions in multiple myeloma. Blood 2002;100:2195–202.[Abstract/Free Full Text]
  7. Choi SJ, Oba Y, Gazitt Y, et al. Antisense inhibition of macrophage inflammatory protein 1-{alpha} blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001;108:1833–41.[CrossRef][Medline]
  8. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-{alpha} is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671–5.[Abstract/Free Full Text]
  9. Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. Macrophage inflammatory protein-1{alpha} is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor {kappa}B ligand. Blood 2001;97:3349–53.[Abstract/Free Full Text]
  10. Hashimoto T, Abe M, Oshima T, et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1{alpha} and MIP-1ß correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol 2004;125:38–41.[CrossRef][Medline]
  11. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998;95:3597–602.[Abstract/Free Full Text]
  12. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165–76.[CrossRef][Medline]
  13. Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 1999;256:449–55.[CrossRef][Medline]
  14. Nakagawa N, Kinosaki M, Yamaguchi K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998;253:395–400.[CrossRef][Medline]
  15. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309–19.[CrossRef][Medline]
  16. Tsurukai T, Udagawa N, Matsuzaki K, Takahashi N, Suda T. Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. J Bone Miner Metab 2000;18:177–84.[CrossRef][Medline]
  17. Niida S, Kaku M, Amano H, et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 1999;190:293–8.[Abstract/Free Full Text]
  18. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001;98:3527–33.[Abstract/Free Full Text]
  19. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 2001;98:11581–6.[Abstract/Free Full Text]
  20. Seidel C, Hjertner O, Abildgaard N, et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001;98:2269–71.[Abstract/Free Full Text]
  21. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003;101:2094–8.[Abstract/Free Full Text]
  22. Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and RANK ligand expression in prostate cancer. Urology 2001;57:611–6.[CrossRef][Medline]
  23. Giuliani N, Colla S, Sala R, et al. Human myeloma cells stimulate the receptor activator of nuclear factor-{kappa}B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 2002;100:4615–21.[Abstract/Free Full Text]
  24. Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor {kappa}B ligand on adult T-cell leukemia cells. Blood 2002;99:634–40.[Abstract/Free Full Text]
  25. Kato I, Sato H, Kudo A. TRANCE together with IL-7 induces pre-B cells to proliferate. Eur J Immunol 2003;33:334–41.[Medline]
  26. Sezer O, Heider U, Jakob C, et al. Immunocytochemistry reveals RANKL expression of myeloma cells. Blood 2002;99:4646–7, author reply 4647.[Free Full Text]
  27. Heider U, Langelotz C, Jakob C, et al. Expression of receptor activator of nuclear factor {kappa}B ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 2003;9:1436–40.[Abstract/Free Full Text]
  28. Farrugia AN, Atkins GJ, To LB, et al. Receptor activator of nuclear factor-{kappa}B ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 2003;63:5438–45.[Abstract/Free Full Text]
  29. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235–44.[Medline]
  30. Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and RANK ligand expression in prostate cancer. Urology 2001;57:611–6.
  31. Manabe N, Kawaguchi H, Chikuda H, et al. Connection between B lymphocyte and osteoclast differentiation pathways. J Immunol 2001;167:2625–31.[Abstract/Free Full Text]
  32. Choi Y, Woo KM, Ko SH, et al. Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. Eur J Immunol 2001;31:2179–88.[CrossRef][Medline]
  33. Tezuka K, Sato T, Kamioka H, et al. Identification of osteopontin in isolated rabbit osteoclasts. Biochem Biophys Res Commun 1992;186:911–7.[CrossRef][Medline]
  34. Quinn JM, Elliott J, Gillespie MT, Martin TJ. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998;139:4424–7.[Abstract/Free Full Text]
  35. Kwon BS, Wang S, Udagawa N, et al. TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J 1998;12:845–54.[Abstract/Free Full Text]
  36. Penno H, Silfversward CJ, Frost A, Brandstrom H, Nilsson O, Ljunggren O. Osteoprotegerin secretion from prostate cancer is stimulated by cytokines, in vitro. Biochem Biophys Res Commun 2002;293:451–5.[CrossRef][Medline]
  37. Matsumoto Y, Tanaka K, Hirata G, et al. Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and the cell proliferation of osteoclast precursor cells in arthritic joints. J Immunol 2002;168:5824–31.[Abstract/Free Full Text]
  38. Henriksen K, Karsdal MA, Delaisse JM, Engsig MT. RANKL and VEGF induce osteoclast chemotaxis through an ERK1/2 dependent mechanism. J Biol Chem 2003;278:48745–53.[Abstract/Free Full Text]
  39. Nagai M, Kyakumoto S, Sato N. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem Biophys Res Commun 2000;269:532–6.[CrossRef][Medline]
  40. Barcala V, Ruybal P, Garcia Rivello H, Waldner C, Ascione A, Mongini C. RANKL expression in a case of follicular lymphoma. Eur J Haematol 2003;70:417–9.[Medline]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
Y. Tanaka, M. Abe, M. Hiasa, A. Oda, H. Amou, A. Nakano, K. Takeuchi, K. Kitazoe, S. Kido, D. Inoue, et al.
Myeloma Cell-Osteoclast Interaction Enhances Angiogenesis Together with Bone Resorption: A Role for Vascular Endothelial Cell Growth Factor and Osteopontin
Clin. Cancer Res., February 1, 2007; 13(3): 816 - 823.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
H. Ichikawa, A. Murakami, and B. B. Aggarwal
1'-Acetoxychavicol Acetate Inhibits RANKL-Induced Osteoclastic Differentiation of RAW 264.7 Monocytic Cells by Suppressing Nuclear Factor-{kappa}B Activation
Mol. Cancer Res., April 1, 2006; 4(4): 275 - 281.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shibata, H.
Right arrow Articles by Matsumoto, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shibata, H.
Right arrow Articles by Matsumoto, T.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online